Pemetrexed and Carboplatin for Locally Advanced or Metastatic Breast Cancer

A new clinical trial is currently underway to explore the effectiveness of a treatment combination for breast cancer. This specific study focuses on patients who have locally advanced or metastatic breast cancer, which means the cancer has either spread to nearby tissues or other parts of the body. The goal is to evaluate the potential benefits of using two drugs, Alimta (pemetrexed) and carboplatin, together in treating this form of breast cancer. The study is important as it aims to find better treatment options for patients with advanced stages of breast cancer, potentially improving their care and quality of life. During this study, participants receive both Alimta and carboplatin as their treatment. The main objective is to assess the antitumor activity of this drug combination, essentially measuring how well the treatment can reduce tumor size. To do this, researchers will monitor the participants' progress throughout the study, observing the changes in tumor size and evaluating the overall effectiveness of the treatment.